IMMURON (IMRN) Stock Price, News & Analysis

Company Overview

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.

Key Stats

• Today's Range: $1.85 to $2.13
• 50-Day Range: $4.80 to $5.61
• 52-Week Range: $1.50 to $2.87
• Volume: 12,391 shs
• Average Volume: 51,952 shs
• Market Capitalization: $12.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Buy

IMMURON Stock Analysis - MarketRank™

IMMURON scored higher than 39% of companies evaluated by MarketBeat, and ranked 761st out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

IMMURON has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

IMMURON has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for IMMURON are expected to decrease in the coming year, from ($0.02) to ($0.03) per share.

Price to Book Value per Share Ratio

IMMURON has a P/B Ratio of 1.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.53% of the outstanding shares of IMMURON have been sold short.

Short Interest Ratio / Days to Cover

IMMURON has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IMMURON has recently decreased by 35.23%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IMMURON does not currently pay a dividend.

Dividend Growth

IMMURON does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.53% of the outstanding shares of IMMURON have been sold short.

Short Interest Ratio / Days to Cover

IMMURON has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in IMMURON has recently decreased by 35.23%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for IMMURON this week, compared to 1 article on an average week.

Search Interest

5 people have searched for IMRN on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IMMURON insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.01% of the stock of IMMURON is held by insiders.

Percentage Held by Institutions

Only 0.12% of the stock of IMMURON is held by institutions.

IMRN Stock Analysis - Frequently Asked Questions

When did IMMURON IPO?

IMMURON (IMRN) raised $6 million in an initial public offering on Friday, June 9th 2017. The company issued 600,000 shares at a price of $9.99 per share. Joseph Gunnar and Rodman & Renshaw (a unit of H.C. Wainwright & Co.) acted as the underwriters for the IPO and WallachBeth Capital was co-manager.

What other stocks do shareholders of IMMURON own?

Based on aggregate information from My MarketBeat watchlists, some other companies that IMMURON investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), AbbVie (ABBV), VBI Vaccines (VBIV), CRISPR Therapeutics (CRSP) and Dynavax Technologies (DVAX).

Company Calendar

• Today: 9/03/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: NASDAQ:IMRN
• CIK: 1660046
• Web: www.immuron.com.au
• Phone: (138) 892-4854
• Fax: 6103 98227735
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for IMMURON: $5.00
• High Price Target: $5.00
• Low Price Target: $5.00
• Potential Upside/Downside: +174.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.80
• Quick Ratio: 5.92

Sales & Book Value

• Annual Sales: $4.72 million
• Price / Sales: 2.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.46 per share
• Price / Book: 1.25

Miscellaneous

• Outstanding Shares: 6,710,000
• Free Float: 6,236,000
• Market Cap: $12.25 million
• Optionable: Not Optionable
• Beta: 0.77